Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Hisamitsu Pharmaceutical Inc (4530)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3,820.0 +44.0    +1.16%
01:59:30 - Closed. Currency in JPY ( Disclaimer )
Type:  Equity
Market:  Japan
ISIN:  JP3784600003 
  • Volume: 81,800
  • Bid/Ask: 3,817.0 / 3,824.0
  • Day's Range: 3,769.0 - 3,824.0
Hisamitsu Pharmaceutical Inc 3,820.0 +44.0 +1.16%

Hisamitsu Pharmaceutical Inc Company Profile

 
Get an in-depth profile of Hisamitsu Pharmaceutical Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

2769

Equity Type

ORD

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to approximately 40 countries and regions, including Asia, the United States of America, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.

Contact Information

Address Tashirodaikan-machi 408
Tosu, 841-0017
Japan
Phone 81 3 5293 1720
Fax 81 3 5293 1724

Top Executives

Name Age Since Title
Kazuhide Nakatomi 51 2007 President, CEO & Director
Keinosuke Ono 83 - Part-time Outside Corporate Auditor
Nobuyuki Nakatomi 83 2008 Standing Corporate Auditor
Munehiko Hirano 76 2006 Standing Corporate Auditor
Teijiro Furukawa 89 2015 Independent Outside Director
Kyu Saito 60 2013 MD, Executive Officer, GM of Global Business & Director
Nobuo Tsutsumi 59 2014 GM of Legal Dept, Prod Environment, Reliability Assurance & Comp Manager, Executive Off and Dir
Shinichi Murayama 56 2014 Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director
Kentaro Watanabe 54 2023 Part Time Outside Corporate Auditor
Yuichiro Anzai 77 2020 Part-time Outside Independent Director
Tamako Watanabe 41 2023 Part Time Outside Independent Director
Koji Takiyama 52 2021 Executive Officer, GM of President's Office & Director
Tetsugo Matsuo 51 2020 Part-time Outside Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

4530 Comments

Write your thoughts about Hisamitsu Pharmaceutical Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email